Xilio Therapeutics (XLO) Change in Accured Expenses (2020 - 2026)

Xilio Therapeutics has reported Change in Accured Expenses for 7 years, with the latest figure at -$1.5 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 75.91% year-over-year to -$1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (up 171.18% YoY) and the FY2025 annual result came in at -$979000.0, up 36.55% from the prior year.
• Change in Accured Expenses fell to -$1.5 million in Q1 2026 per XLO's latest filing, from $928000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $4.6 million in Q2 2022 and troughed at -$6.4 million in Q1 2025.
• A 5-year average of -$135176.5 and a median of $664000.0 in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses sank 929.33% in 2022, then soared 1669.67% in 2025.
• Over 5 years, Change in Accured Expenses stood at $1.5 million in 2022, then declined by 24.91% to $1.1 million in 2023, then tumbled by 107.71% to -$85000.0 in 2024, then surged by 1191.76% to $928000.0 in 2025, then tumbled by 265.52% to -$1.5 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$1.5 million, $928000.0, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.